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A 66-year-old man with a history of multiple transurethral resections for recurrent 
bladder tumors, staged as Ta according to the International Union Against Cancer stag-
ing guidelines, presented with a complaint of dry cough. A round nodule with a diameter 
of 7.5 cm was detected in the lung by chest computed tomography, and a video-assisted 
thoracoscopic lobectomy was performed. Pulmonary metastasis of recurrent bladder 
cancer was diagnosed by immunohistochemistry staining for the urothelium-specific 
protein uroplakin Ia. Subsequently, 2 cycles of systemic chemotherapy were admini-
stered. Two and a half years after treatment, no recurrence of pulmonary lesions has 
been detected. A combination of complete resection of pulmonary lesions and systemic 
chemotherapy may result in a good prognosis for patients with non-muscle-invasive 
bladder cancer.
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Nonmuscle-invasive bladder cancer seldom shows distant 
metastasis. In addition, it is extremely rare for bladder can-
cer staged as Ta under the International Union Against 
Cancer guidelines to result in distant metastasis. We pres-
ent the case of a patient with a distant pulmonary meta-
stasis of Ta bladder cancer; the patient did not have a his-
tory of muscle-invasive disease. We review the literature 
concerning non-muscle-invasive bladder cancer with dis-
tant metastasis and discuss management and treatment 
outcomes.
CASE REPORT
A 66-year-old man had been diagnosed with Ta bladder 
cancer 6 years before he complained of dry cough in July 
2009. He had a history of recurrent non-muscle-invasive 
bladder tumors and had therefore undergone 7 transure-
thral resections (TURs) and had received intravesicular 
chemotherapies (8 cycles of weekly mitomycin-C after the 
4th TUR and 5 cycles of biweekly pirarubicin after the 5th 
TUR). All tumors were ＜1 cm, well pedunculated, and 
papillary. The number of tumors ranged from 1 to 6 in each 
respective TUR. The pathological findings of all TURs in-
dicated the presence of urothelial carcinoma (stage Ta 
without carcinoma in situ, grade 1 or 2) without lymphatic 
or vascular invasion. The last TUR in January 2009 showed 
the same findings as the previous TURs, i.e., there were 3 
tiny papillary tumors located at the right lateral wall, at 
the posterior wall, and adjacent to the left ureteral orifice, 
and pathological examination indicated results similar to 
those of the previous TURs. Chest radiography at 6 months 
after the last TUR detected a round nodule (diameter, 7.5 
cm) in the right lower lung. We carefully rechecked the 
chest radiograph obtained in April 2008, which showed a 
small nodule (diameter, 1 cm) in the same area. These ob-
servations suggest that the lung metastasis had occurred 
more than 1 year previously. The initial diagnosis based on 
the computed tomography findings was primary lung can-
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FIG. 1. A computed tomography scan showing a large mass in the 
upper lobe of the right lung.
FIG. 2. Uroplakin Ia (UP-Ia) staining in bladder urothelial carcinoma and lung metasitasis (×200; bar=200 μm). (A) Bladder urothelial 
carcinoma shows diffuse cytoplasmic staining and umbrella cells show strong immunoreaction for UP-Ia. (B) Moderate positive 
immunostaining in lung metastasis.
cer (Fig. 1). Therefore, initial treatment consisted of vid-
eo-assisted thoracoscopic lobectomy. The histopathologic 
features of the pulmonary lesion and the TUR specimen of 
the bladder cancer were qualitatively similar. Immunohis-
tochemistry showed that both the TUR specimen and the 
pulmonary lesion were positive for the urothelium-specific 
protein uroplakin Ia (UP-Ia) [1] (Fig. 2). On the basis of 
these findings, the patient was diagnosed with pulmonary 
metastasis of recurrent Ta bladder cancer. Subsequently, 
he received 2 cycles of postoperative chemotherapy with 
the same gemcitabine and cisplatin regimen reported by 
von der Maase et al. [2]. Although we had planned 3 cycles 
of chemotherapy, the patient refused the third course. His 
bladder cancer recurred at 3 and 8 months after chemo-
therapy and hence he underwent TUR both times. The re-
sults of the pathological examination were the same results 
as for the previous TURs. Two and a half years after chemo-
therapy, chest and abdominal computed tomography once 
every 3 months detected no recurrence of the pulmonary 
lesions or other distant metastasis.
DISCUSSION
For nonmuscle-invasive bladder cancer, the probability of 
recurrence at 5 years ranges from 31% to 78% [3], whereas 
the risk of distant metastasis is extremely low. Matthew 
et al. [4] reviewed cases of more than 1,000 patients treated 
for bladder cancer, regardless of the stage, and identified 
9 patients with superficial urothelial carcinoma and dis-
tant metastatic disease (including 3 patients with stage 
pTa disease). Three patients underwent radical cys-
tectomy, and muscle invasion was not identified on patho-
logical examination [4]. Because vessels are absent in the 
bladder mucosa, it is thought that Ta bladder cancer does 
not have the potential for lymphatic or hematogenous 
metastasis. Several iatrogenic mechanisms of metastasis 
in clinically diagnosed Ta cancer have been postulated: mi-
croscopic invasion by an understaged tumor, intravascular 
dissemination of tumor cells during transurethral re-
section, and degeneration of the basal membrane caused 
by intravesicular therapy [5]. 
It is often difficult to definitively diagnose pulmonary 
metastasis of bladder cancer. Histopathologic features of 
non-keratinized squamous-cell carcinoma of the lung are 
similar to those of urothelial carcinoma. Uroplakins (UPs) 
are urothelium-specific proteins and have 4 subtypes: Ia, 
Ib, II, and III. Kageyama et al. [1] reported that UP-Ia has 
higher sensitivity for urothelial carcinoma than UPs II and 
III. They investigated the expression of UP-Ia in primary 
and metastatic urothelial carcinoma. Among primary and 
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TABLE 1. Summary of the literature reporting patients with lung metastasis of nonmuscle-invasive bladder cancer




Seymour et al., 1972 [7]
Matthews et al., 1984 [4]
Matthews et al., 1984 [4]
Matthews et al., 1984 [4]
Koh, et al., 1994 [8]
Dougherty et al., 2009 [9]




































DOD at 1 mo
Not available
NED
More than 24 mo NED
36 mo NED
6 mo NED
NED, no evidence of disease; DOD, died of disease. 
Tumor grade was evaluated using 1973 World Health Organization (WHO) grading. 
a:Low grade was evaluated using 2004 WHO grading. 
metastatic lesions, the detection rate of UP-Ia was 96.8% 
and 72.2%, respectively. UP-Ia can be a promising marker 
for identifying urothelial carcinoma.
To the best of our knowledge, 15 cases of non-muscle-in-
vasive bladder cancer with distant metastasis have been 
reported in the English literature. Metastatic sites include 
the lungs, liver, bones, ovaries, and brain. Furthermore, 7 
cases of lung metastasis have been reported (Table 1). All 
patients with bone metastasis (including 2 with stage pTa 
disease) died shortly after diagnosis [4], and 1 patient with 
solitary brain metastasis died less than 3 months after 
brain surgery [6]. On the other hand, as indicated in Table 
1, the outcomes in most patients with lung metastasis were 
good, except for 1 patient (stage Ta, grade 2) who died 1 
month after diagnosis [4]. Other studies have demon-
strated a good prognosis in 3 patients with Ta bladder can-
cer and lung metastasis after a combination of lobectomy 
and neoadjuvant or adjuvant chemotherapy [7-9]. Death 
due to pulmonary metastasis of Ta bladder cancer has not 
been reported, because the malignant potential of the 
metastatic lesions is low, and metastatic lesions can be 
completely resected with ease. Although the effects of ad-
juvant chemotherapy remain undetermined, some au-
thors have reported that adjuvant chemotherapy may con-
tribute to the removal of systemically circulating cancer 
cells.
A combination of complete resection of the lung lesions 
and systemic chemotherapy may lead to good prognosis for 
patients with non-muscle-invasive bladder cancer.
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